SI-BONE INC (SIBN)
US8257041090 - Common Stock
SIBN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Health Care Equipment & Supplies industry. The financial health of SIBN is average, but there are quite some concerns on its profitability. SIBN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SIBN had negative earnings in the past year.
SIBN had a negative operating cash flow in the past year.
SIBN had negative earnings in each of the past 5 years.
In the past 5 years SIBN always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -18.81%, SIBN perfoms like the industry average, outperforming 55.73% of the companies in the same industry.
SIBN has a Return On Equity (-25.59%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.81% | ||
| ROE | -25.59% | ||
| ROIC | N/A |
ROA(3y)-29.14%
ROA(5y)-27.96%
ROE(3y)-43.35%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SIBN's Gross Margin of 78.78% is amongst the best of the industry. SIBN outperforms 90.63% of its industry peers.
SIBN's Gross Margin has declined in the last couple of years.
SIBN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.57%
GM growth 5Y-2.87%
2. Health
2.1 Basic Checks
SIBN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SIBN has been increased compared to 1 year ago.
Compared to 5 years ago, SIBN has more shares outstanding
The debt/assets ratio for SIBN has been reduced compared to a year ago.
2.2 Solvency
SIBN has an Altman-Z score of 4.21. This indicates that SIBN is financially healthy and has little risk of bankruptcy at the moment.
SIBN has a Altman-Z score of 4.21. This is in the better half of the industry: SIBN outperforms 73.96% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SIBN is not too dependend on debt financing.
SIBN's Debt to Equity ratio of 0.21 is in line compared to the rest of the industry. SIBN outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.21 |
ROIC/WACCN/A
WACC9.82%
2.3 Liquidity
SIBN has a Current Ratio of 9.01. This indicates that SIBN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 9.01, SIBN belongs to the top of the industry, outperforming 88.54% of the companies in the same industry.
SIBN has a Quick Ratio of 8.15. This indicates that SIBN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SIBN (8.15) is better than 89.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.01 | ||
| Quick Ratio | 8.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.31% over the past year.
SIBN shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.52%.
The Revenue has been growing by 20.18% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.31%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q15.62%
Revenue 1Y (TTM)30.52%
Revenue growth 3Y23.69%
Revenue growth 5Y20.18%
Revenue growth Q2Q21.62%
3.2 Future
Based on estimates for the next years, SIBN will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.23% on average per year.
SIBN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.00% yearly.
EPS Next Y11.59%
EPS Next 2Y14.71%
EPS Next 3Y18.23%
EPS Next 5YN/A
Revenue Next Year19.22%
Revenue Next 2Y18.4%
Revenue Next 3Y17%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SIBN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SIBN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SIBN's earnings are expected to grow with 18.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.71%
EPS Next 3Y18.23%
5. Dividend
5.1 Amount
SIBN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SI-BONE INC
NASDAQ:SIBN (5/6/2024, 7:27:26 PM)
After market: 14.5 +0.02 (+0.14%)14.48
+0.28 (+1.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap594.55M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.81% | ||
| ROE | -25.59% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.78% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.01 | ||
| Quick Ratio | 8.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)36.31%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y11.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)30.52%
Revenue growth 3Y23.69%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y